Literature DB >> 23196713

Benchmarking therapeutic drug monitoring software: a review of available computer tools.

Aline Fuchs1, Chantal Csajka, Yann Thoma, Thierry Buclin, Nicolas Widmer.   

Abstract

Therapeutic drug monitoring (TDM) aims to optimize treatments by individualizing dosage regimens based on the measurement of blood concentrations. Dosage individualization to maintain concentrations within a target range requires pharmacokinetic and clinical capabilities. Bayesian calculations currently represent the gold standard TDM approach but require computation assistance. In recent decades computer programs have been developed to assist clinicians in this assignment. The aim of this survey was to assess and compare computer tools designed to support TDM clinical activities. The literature and the Internet were searched to identify software. All programs were tested on personal computers. Each program was scored against a standardized grid covering pharmacokinetic relevance, user friendliness, computing aspects, interfacing and storage. A weighting factor was applied to each criterion of the grid to account for its relative importance. To assess the robustness of the software, six representative clinical vignettes were processed through each of them. Altogether, 12 software tools were identified, tested and ranked, representing a comprehensive review of the available software. Numbers of drugs handled by the software vary widely (from two to 180), and eight programs offer users the possibility of adding new drug models based on population pharmacokinetic analyses. Bayesian computation to predict dosage adaptation from blood concentration (a posteriori adjustment) is performed by ten tools, while nine are also able to propose a priori dosage regimens, based only on individual patient covariates such as age, sex and bodyweight. Among those applying Bayesian calculation, MM-USC*PACK© uses the non-parametric approach. The top two programs emerging from this benchmark were MwPharm© and TCIWorks. Most other programs evaluated had good potential while being less sophisticated or less user friendly. Programs vary in complexity and might not fit all healthcare settings. Each software tool must therefore be regarded with respect to the individual needs of hospitals or clinicians. Programs should be easy and fast for routine activities, including for non-experienced users. Computer-assisted TDM is gaining growing interest and should further improve, especially in terms of information system interfacing, user friendliness, data storage capability and report generation.

Entities:  

Mesh:

Year:  2013        PMID: 23196713     DOI: 10.1007/s40262-012-0020-y

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  44 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  [Clinically important food-drug interactions: what the practitioner needs to know].

Authors:  N Corti; A B Taegtmeyer
Journal:  Praxis (Bern 1994)       Date:  2012-06-20

3.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring.

Authors:  J H Proost; D K Meijer
Journal:  Comput Biol Med       Date:  1992-05       Impact factor: 4.589

4.  Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.

Authors:  Verena Gotta; Nicolas Widmer; Michael Montemurro; Serge Leyvraz; Amina Haouala; Laurent A Decosterd; Chantal Csajka; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

5.  Computer-assisted therapeutic drug monitoring.

Authors:  R J Elin
Journal:  Clin Lab Med       Date:  1987-06       Impact factor: 1.935

Review 6.  Computers in pharmacokinetics. Choosing software for clinical decision making.

Authors:  D E Buffington; V Lampasona; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 7.  Computer-assisted decision making in medicine.

Authors:  J C Kunz; E H Shortliffe; B G Buchanan; E A Feigenbaum
Journal:  J Med Philos       Date:  1984-05

8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

Review 10.  Computerized advice on drug dosage to improve prescribing practice.

Authors:  Pierre Durieux; Ludovic Trinquart; Isabelle Colombet; Julie Niès; Rt Walton; Anand Rajeswaran; Myriam Rège Walther; Emma Harvey; Bernard Burnand
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16
View more
  43 in total

1.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

Review 2.  Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.

Authors:  Stefanie L Groenland; Ron H J Mathijssen; Jos H Beijnen; Alwin D R Huitema; Neeltje Steeghs
Journal:  Eur J Clin Pharmacol       Date:  2019-06-07       Impact factor: 2.953

3.  Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy.

Authors:  Lana Nezic; Adrian Derungs; Marcel Bruggisser; Sarah Tschudin-Sutter; Stephan Krähenbühl; Manuel Haschke
Journal:  Eur J Clin Pharmacol       Date:  2014-04-23       Impact factor: 2.953

Review 4.  Optimising antimicrobial therapy through the use of Bayesian dosing programs.

Authors:  M L Avent; B A Rogers
Journal:  Int J Clin Pharm       Date:  2019-08-07

5.  Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.

Authors:  João A Abrantes; Siv Jönsson; Mats O Karlsson; Elisabet I Nielsen
Journal:  Br J Clin Pharmacol       Date:  2019-04-29       Impact factor: 4.335

Review 6.  Opportunities for model-based precision dosing in the treatment of sickle cell anemia.

Authors:  Min Dong; Tomoyuki Mizuno; Alexander A Vinks
Journal:  Blood Cells Mol Dis       Date:  2017-08-09       Impact factor: 3.039

Review 7.  Dashboard systems: implementing pharmacometrics from bench to bedside.

Authors:  Diane R Mould; Richard N Upton; Jessica Wojciechowski
Journal:  AAPS J       Date:  2014-06-20       Impact factor: 4.009

8.  The performance of contemporary cystatin C-based GFR equations in predicting gentamicin clearance.

Authors:  Paul K L Chin; Janice S C Chew-Harris; Christopher M Florkowski; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

9.  Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.

Authors:  Aline Fuchs; Monia Guidi; Eric Giannoni; Dominique Werner; Thierry Buclin; Nicolas Widmer; Chantal Csajka
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

Review 10.  Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.

Authors:  Min Dong; Patrick T McGann
Journal:  Clin Pharmacol Ther       Date:  2020-10-08       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.